Pallasite Ventures
VC Fund
Chicago, United States
Pallasite Ventures is a VC fund in Chicago focused on Software and Health Care. Pallasite Ventures provides early-stage financing for high-growth companies across a variety of industries. It was founded by David Light and is based in Chicago, Illinois.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Pallasite Ventures invests in
SoftwareHealth CareBiotechnologyMobileArtificial Intelligence
Stages Pallasite Ventures invests in
SeedSeries ASeries BSeries CFunding Round
Countries Pallasite Ventures invests in
CanadaUnited States
Round sizes
Seed $988k–$5MSeries A $3.2M–$20MSeries B $14M–$115M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $988k–$5M
- Series A
- $3.2M–$20M
- Series B
- $14M–$115M
Investment Focus
Industry
- Software 6 (17%)
- Health Care 6 (17%)
- Biotechnology 5 (14%)
- Mobile 4 (11%)
- Artificial Intelligence 4 (11%)
Stage
- Seed 16 (46%)
- Series A 7 (20%)
- Series B 2 (6%)
- Series C 2 (6%)
- Funding Round 2 (6%)
Country
- Canada 12 (34%)
- United States 12 (34%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christopher Bissonnette
Managing Partner
|
Managing Partner | Total investments: 5 | Find email | |
Christopher Bissonnette
Managing Partner
|
Managing Partner | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aspect Biosystems
|
Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $115M / Series B / Jan 08, 2025 | |
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $20M / Series A / Dec 05, 2023 | |
|
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $20M / Series A / Dec 05, 2023 | |
Oncoustics AI
|
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers. | $5M / Seed / Jul 21, 2022 | |
Zeno Power
|
Zeno Power is a company that creates advanced power systems that use radioisotopes. The company intends to increase the production of small-scale nuclear batteries capable of powering spacecraft and undersea technologies for years.Zeno, founded in 2018 by three Vanderbilt University students, intends to be the first to enter the commercial marketwith a novel new combination of affordability and lightweight. | $20M / Series A / Apr 26, 2022 | |
|
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $14.9M / Series A / Jan 19, 2022 | |
|
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $14.9M / Series A / Jan 19, 2022 | |
Prescryptive Health
|
Prescryptive Health is a digital health company focused on improving the prescription drug market | $26M / Series A / Aug 25, 2020 | |
|
Aspect Biosystems
|
Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $20M / Series A / Jan 09, 2020 | |
|
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $3M / Seed / Dec 17, 2019 | |
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Mobile Investors
12,672 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Pallasite Ventures invest in?
Pallasite Ventures invests primarily in Software, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 35 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pallasite Ventures's check size?
Pallasite Ventures typically joins rounds of $988k–$5M at Seed, $3.2M–$20M at Series A and $14M–$115M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pallasite Ventures participates in.
How do I contact Pallasite Ventures?
Public channels for Pallasite Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pallasite Ventures?
The team at Pallasite Ventures includes Christopher Bissonnette (Managing Partner) and Christopher Bissonnette (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
